<?xml version="1.0" encoding="UTF-8"?>
<p>As new immune-modulatory therapeutics enter the clinical arena, further assessment related to chronic viral infection is necessary. Building on guidelines from the American Gastroenterological Association,
 <xref rid="R4" ref-type="bibr">4</xref> the American Society of Clinical Oncology (ASCO) has published provisional clinical opinions outlining the scenarios for viral screening prior to cancer therapy.
 <xref rid="R5" ref-type="bibr">5</xref> Both reports define patient-related risk factors for latent HBV infection, and therapies associated with high risk of HBV reactivation.
 <xref rid="R4" ref-type="bibr">4 5</xref> This should have further wide dissemination to the oncology community. Differences in screening recommendations continue to be discussed.
 <xref rid="R2" ref-type="bibr">2â€“5</xref>
</p>
